Table 3.
Secondary outcomes
| Thromboembolic outcomes | Apixaban (n = 28) | Warfarin (n = 733) | P |
|---|---|---|---|
| Total events, % | 5.5 | 10.3 | .08 |
| NSTEMI, n (%) | 5 (3.9) | 21 (2.9) | .572 |
| STEMI, n (%) | 0 (0) | 6 (0.8) | .6 |
| CVA, n (%) | 0 (0) | 10 (1.4) | .374 |
| DVT, n (%) | 1 (0.8) | 23 (3.1) | .238 |
| PE, n (%) | 0 (0) | 4 (0.5) | 1.0 |
| Cardiac thrombus, n (%) | 1 (0.8) | 12 (1.6) | .704 |
| Clot severity, n (%) | |||
| Major | 1 (0.8) | 9 (1.2) | .634 |
| Minor | 5 (3.9) | 43 (5.9) | |
| Minimal | 0 (0) | 8 (1.1) | |
| Bleeding outcomes, % | 5.5 | 10.9 | |
| Brain, n (%) | 0 (0) | 5 (0.7) | .06 |
| GI bleed, n (%) | 6 (4.7) | 67 (9.1) | |
| Hematuria, n (%) | 1 (0.8) | 6 (0.8) | |
| Other, n (%) | 0 (0) | 2 (0.3) | |
| Bleed severity, n (%) | |||
| Major | 1 (0.8) | 12 (1.6) | .474 |
| Minor | 5 (3.9) | 61 (8.3) | |
| Minimal | 1 (0.8) | 3 (0.4) | |
CVA, cerebrovascular accident; GI, gastrointestinal; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.